Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25373730 | 0.81 | HSD17B10 (0.53) | HSD17B10NAPRTLMNACYP1A2CYP2C19 | |
| SCHEMBL229639 | 0.77 | LMNA (0.58) | HSD17B10NAPRTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL647632 | 0.77 | HSD17B10 (0.64) | HSD17B10NAPRTLMNACYP1A2CYP2C19 | |
| SCHEMBL9298215 | 0.76 | ALDH1A1 (0.62) | LMNACYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL7989066 | 0.75 | L3MBTL1 (0.50) | HSD17B10LMNACYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL21397880 | 0.75 | HSD17B10 (0.61) | HSD17B10NAPRTLMNACYP1A2CYP2C19 | |
| SCHEMBL9364280 | 0.74 | CES2 (0.50) | LMNASMN1; SMN2CYP2C9L3MBTL1KMT2A | |
| SCHEMBL1377356 | 0.74 | CES2 (0.50) | LMNASMN1; SMN2ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL15846816 | 0.74 | LMNA (0.52) | LMNACYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL11125513 | 0.74 | L3MBTL1 (0.49) | HSD17B10LMNAALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | claimed |
| CN-114344186-A | Pigment stabilizer | C·扎维拉 | 2022-04-15 | — | — | CN | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| EP-0927192-B1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-0590348-B1 | Central venous catheters loaded with lipodalbaheptide antibiotics preventing development of catheter related infections | AVENTIS BULK S P A (IT) | 2002-02-27 | — | — | EP | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| EP-0680469-B1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-04-26 | — | — | EP | disclosed |
| US-5807875-A | OBESITY THERAPY | DR. KARL THOMAE GMBH (DE) | 1998-09-15 | — | — | US | disclosed |
| US-5750509-A | TREATMENT AGAINST INFECTIONS BY BACTERIA INCLUDING ENTEROCOCCUS, AND STAPHYLOCOCCUS | GRUPPO LEPETIT S.P.A. (IT) | 1998-05-12 | — | — | US | disclosed |
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | disclosed |
| EP-0680469-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1995-11-08 | — | — | EP | disclosed |
| EP-0596929-B1 | AMIDE DERIVATIVES OF ANTIBIOTIC A 40926 | LEPETIT SPA (IT) | 1995-07-26 | — | — | EP | disclosed |
| WO-1994017035-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1994-08-04 | — | — | WO | disclosed |
| EP-0590348-A1 | Central venous catheters loaded with lipodalbaheptide antibiotics preventing development of catheter related infections | GRUPPO LEPETIT S.p.A. (IT) | 1994-04-06 | — | — | EP | disclosed |
| WO-1993003060-A1 | AMIDE DERIVATIVES OF ANTIBIOTIC A 40926 | GRUPPO LEPETIT S.P.A. (IT) | 1993-02-18 | — | — | WO | disclosed |
| EP-0525499-A1 | Amide derivatives of antibiotic A 40926 | GRUPPO LEPETIT S.p.A. (IT) | 1993-02-03 | — | — | EP | disclosed |
| EP-0434365-A2 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | HSD17B10 4618/4885NAPRT 4093/4885LMNA 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.